The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000527.5(LDLR):c.1329G>C (p.Trp443Cys)

CA10585409

251792 (ClinVar)

Gene: LDLR
Condition: hypercholesterolemia, familial
Inheritance Mode: Semidominant inheritance
UUID: a2f5cf0c-e5f9-4215-a7eb-690c2673a2de
Approved on: 2025-01-31
Published on: 2025-02-03

HGVS expressions

NM_000527.5:c.1329G>C
NM_000527.5(LDLR):c.1329G>C (p.Trp443Cys)
NC_000019.10:g.11113420G>C
CM000681.2:g.11113420G>C
NC_000019.9:g.11224096G>C
CM000681.1:g.11224096G>C
NC_000019.8:g.11085096G>C
NG_009060.1:g.29040G>C
ENST00000252444.10:c.1587G>C
ENST00000559340.2:c.1329G>C
ENST00000560467.2:c.1209G>C
ENST00000558518.6:c.1329G>C
ENST00000252444.9:c.1583G>C
ENST00000455727.6:c.825G>C
ENST00000535915.5:c.1206G>C
ENST00000545707.5:c.948G>C
ENST00000557933.5:c.1329G>C
ENST00000558013.5:c.1329G>C
ENST00000558518.5:c.1329G>C
ENST00000559340.1:c.50G>C
ENST00000560173.1:n.328G>C
ENST00000560467.1:c.809G>C
NM_000527.4:c.1329G>C
NM_001195798.1:c.1329G>C
NM_001195799.1:c.1206G>C
NM_001195800.1:c.825G>C
NM_001195803.1:c.948G>C
NM_001195798.2:c.1329G>C
NM_001195799.2:c.1206G>C
NM_001195800.2:c.825G>C
NM_001195803.2:c.948G>C
More

Pathogenic

Met criteria codes 5
PS4 PP4 PP3 PM2 PP1_Strong
Not Met criteria codes 1
PM5

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Familial Hypercholesterolemia Expert Panel Specifications to the ACMG/AMP Variant Classification Guidelines Version 1.2

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Familial Hypercholesterolemia VCEP
The NM_000527.5(LDLR):c.1329G>C (p.Trp443Cys) variant is classified as Pathogenic for Familial Hypercholesterolemia by applying ACMG/AMP evidence codes PS4, PP1_Strong, PM2, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (specification version 1.2) on 31 January 2025. The supporting evidence is as follows: PM2: PopMax MAF = 0.0000007200 (0.00007200%) in European (non-Finnish) exomes (gnomAD v4.1.0). PP3: REVEL = 0.961. PS4, PP4: Variant meets PM2 and is identified in at least 14 unrelated index cases who fulfill FH criteria from different labs (5 cases with DLCN score >=6 and 5 cases with possible FH by Simon Broome criteria from Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière, France; 2 cases with DLCN score >=6 and 2 cases with possible FH by Simon Broome criteria from Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France). PP1_Strong: Variant segregates with FH phenotype in at least 6 informative meioses from 5 families from different labs (Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies, APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière, France; Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France): 6 affected family members have the variant.
Met criteria codes
PS4
Variant meets PM2 and is identified in at least 14 unrelated index cases who fulfill SB possible or DLCN>=6 criteria for FH from different labs: - 5 unrelated probands with Dutch lipid clinic network >=6 and 5 unrelated probands with Simon Broome possible (Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière). - 2 unrelated probands with DLCN >or = 6 and 2 unrelated probands with Simon Broome possible (Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France).
PP4
Variant meets PM2 and is identified in at least 1 index case who fulfills DLCN>=6 criteria for FH after alternative causes of high cholesterol were excluded (Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière).
PP3
REVEL = 0.961
PM2
PopMax MAF = 0.0000007200 (0.00007200%) in European (non-Finnish) exomes (gnomAD v4.1.0).
PP1_Strong
Variant segregates with FH phenotype in at least 6 informative meioses from 5 families from different labs: - Data from 3 families. P3 family : 1 family member positive for variant with LDL-C >75th percentile. P6 family : 1 family member positive for variant with LDL-C >75th percentile. P7 family : 1 family member positive for variant with LDL-C >75th percentile (Centre de Génétique Moléculaire et Chromosomique, Unité de génétique de l'Obésité et des Dyslipidémies (APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière) - Data from 2 families. Family 1 : 2 family members positive for variant with LDL-C >75th percentile ; Family 2: 1 family member positive for variant with LDL-C >75th percentile (Service de Biochimie et de Biologie Moléculaire, Hospices Civils de Lyon, Lyon, France).
Not Met criteria codes
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.